Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team is scheduled to present on September 10, 2024, at 10:00 AM ET / 7:00 AM PT.
Investors and interested parties can access a live webcast of the presentation through Savara's official website at www.savarapharma.com/investors/events-presentations/. The webcast will remain archived for 90 days after the event, allowing those unable to attend the live presentation to review the content later.
Savara Inc. (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica specializzata in malattie respiratorie rare, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Il team di gestione dell'azienda presenterà il 10 settembre 2024, alle 10:00 AM ET / 7:00 AM PT.
Gli investitori e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso il sito ufficiale di Savara all'indirizzo www.savarapharma.com/investors/events-presentations/. Il webcast rimarrà archiviato per 90 giorni dopo l'evento, consentendo a coloro che non possono partecipare alla presentazione dal vivo di rivedere il contenuto in seguito.
Savara Inc. (Nasdaq: SVRA), una empresa biofarmacéutica en etapa clínica centrada en enfermedades respiratorias raras, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El equipo de gestión de la empresa tiene programada una presentación el 10 de septiembre de 2024, a las 10:00 AM ET / 7:00 AM PT.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web oficial de Savara en www.savarapharma.com/investors/events-presentations/. El webcast permanecerá archivado por 90 días después del evento, lo que permitirá a aquellos que no puedan asistir a la presentación en vivo revisar el contenido más tarde.
사바라 Inc. (Nasdaq: SVRA)는 희귀 호흡기 질환에 주력하는 임상 단계의 생물 의약품 회사로, H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 경영진 팀은 2024년 9월 10일 오전 10시 ET / 오전 7시 PT에 발표할 예정입니다.
투자자와 관련자는 Savara의 공식 웹사이트 www.savarapharma.com/investors/events-presentations/를 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 웹캐스트는 이벤트 종료 후 90일 동안 아카이브되어, 실시간 발표에 참석하지 못한 분들이 나중에 내용을 검토할 수 있도록 합니다.
Savara Inc. (Nasdaq: SVRA), une société bio-pharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'équipe de direction de l'entreprise doit faire une présentation le 10 septembre 2024, à 10h00 ET / 7h00 PT.
Les investisseurs et les parties intéressées peuvent accéder à un webcast en direct de la présentation via le site Web officiel de Savara à l'adresse www.savarapharma.com/investors/events-presentations/. Le webcast restera archivé pendant 90 jours après l'événement, permettant à ceux qui n'ont pas pu assister à la présentation en direct de revoir le contenu par la suite.
Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf seltene Atemwegserkrankungen spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Das Management-Team des Unternehmens wird am 10. September 2024 um 10:00 Uhr ET / 7:00 Uhr PT präsentieren.
Investoren und Interessierte können über die offizielle Website von Savara unter www.savarapharma.com/investors/events-presentations/ auf einen Live-Webcast der Präsentation zugreifen. Der Webcast bleibt 90 Tage lang archiviert, sodass Personen, die nicht an der Live-Präsentation teilnehmen konnten, den Inhalt später überprüfen können.
- None.
- None.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903510959/en/
Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366
Source: Savara Inc.
FAQ
When is Savara (SVRA) presenting at the H.C. Wainwright Global Investment Conference?
How can I watch Savara's (SVRA) presentation at the H.C. Wainwright conference?
How long will Savara's (SVRA) presentation webcast be available after the conference?
What is the focus of Savara (SVRA) as a biopharmaceutical company?
